TNGX · NASDAQ · STOCK
Tango Therapeutics (TNGX) Stock Analysis
$23.82
52W $6.69 – $34.39
55/100
$3.88B
-28.0
1.17
Is TNGX Bullish or Bearish?
Mixed.
Innellis AI committee rates Tango Therapeutics, Inc. (TNGX) Watch with a composite score of 55/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.14 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.86 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 121.5% YoY -- genuine top-line momentum — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -25.7% -- cheap may mean cheap for a reason — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 19.3% signals elevated volatility — Risk
- No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
55/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 66%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -25.7% -- cheap may mean cheap for a reason
Growth Analyst
neutral
47
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 121.5% YoY -- genuine top-line momentum
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 19.3% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 54.9 to 54.9.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
54.5
Neutral
MACD Histogram
-0.060
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$21.65
Resistance
$28.39
Bollinger %B
0.53
Inside Bands
Price vs Moving Averages
EMA 9
$23.22
Above
EMA 21
$23.59
Above
EMA 50
$24.37
Below
EMA 200
$21.26
Above
Fundamental Analysis
Valuation
90
Growth
54
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-28.0×
P/B Ratio
3.48×
PEG Ratio
-0.71
Dividend Yield
0.00%
52W High
$34.39
52W Low
$6.69
Quality & Growth
ROE
-2934.7%
ROA
-2548.2%
Gross Margin
9824.9%
Operating Margin
-25337.9%
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
P/E ratio of -28.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.5x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -29.3%; Return on assets of -25.5%; Net margin of -229.9%; Gross margin of 98.2%; Current ratio of 50.82 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-0.96); Most recent quarter missed estimates by 13.9%; 2 consecutive earnings misses; EPS growth decelerating (-10.3% -> -15.6% QoQ); Average YoY EPS growth of -5.7%; Analyst estimates rising over recent quarters
Get the Full TNGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →